These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 22995909)

  • 1. Histone deacetylase inhibitor (HDACi) suberoylanilide hydroxamic acid (SAHA)-mediated correction of α1-antitrypsin deficiency.
    Bouchecareilh M; Hutt DM; Szajner P; Flotte TR; Balch WE
    J Biol Chem; 2012 Nov; 287(45):38265-78. PubMed ID: 22995909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measuring the Effect of Histone Deacetylase Inhibitors (HDACi) on the Secretion and Activity of Alpha-1 Antitrypsin.
    Wang C; Bouchecareilh M; Balch WE
    Methods Mol Biol; 2017; 1639():185-193. PubMed ID: 28752458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Alpha-1-antitrypsin deficiency].
    Bouchecareilh M
    Med Sci (Paris); 2014 Oct; 30(10):889-95. PubMed ID: 25311024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accumulation of mutant alpha1-antitrypsin Z in the endoplasmic reticulum activates caspases-4 and -12, NFkappaB, and BAP31 but not the unfolded protein response.
    Hidvegi T; Schmidt BZ; Hale P; Perlmutter DH
    J Biol Chem; 2005 Nov; 280(47):39002-15. PubMed ID: 16183649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SAHA enhances Proteostasis of epilepsy-associated α1(A322D)β2γ2 GABA(A) receptors.
    Di XJ; Han DY; Wang YJ; Chance MR; Mu TW
    Chem Biol; 2013 Dec; 20(12):1456-68. PubMed ID: 24211135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
    Negmeldin AT; Knoff JR; Pflum MKH
    Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural Requirements of Histone Deacetylase Inhibitors: SAHA Analogs Modified on the Hydroxamic Acid.
    Bieliauskas AV; Weerasinghe SV; Negmeldin AT; Pflum MK
    Arch Pharm (Weinheim); 2016 May; 349(5):373-82. PubMed ID: 27062198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteostasis strategies for restoring alpha1-antitrypsin deficiency.
    Bouchecareilh M; Conkright JJ; Balch WE
    Proc Am Thorac Soc; 2010 Nov; 7(6):415-22. PubMed ID: 21030523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-α through up-regulation of TNF receptor 1 in lung cancer cells.
    You BR; Han BR; Park WH
    Oncotarget; 2017 Mar; 8(11):17726-17737. PubMed ID: 28099148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibition is cytotoxic to oligodendrocyte precursor cells in vitro and in vivo.
    Dincman TA; Beare JE; Ohri SS; Gallo V; Hetman M; Whittemore SR
    Int J Dev Neurosci; 2016 Nov; 54():53-61. PubMed ID: 27587342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suberoylanilide hydroxamic acid (SAHA)-induced dynamics of a human histone deacetylase protein interaction network.
    Sardiu ME; Smith KT; Groppe BD; Gilmore JM; Saraf A; Egidy R; Peak A; Seidel CW; Florens L; Workman JL; Washburn MP
    Mol Cell Proteomics; 2014 Nov; 13(11):3114-25. PubMed ID: 25073741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of an inhibitor of Z-alpha1 antitrypsin polymerization.
    Berthelier V; Harris JB; Estenson KN; Baudry J
    PLoS One; 2015; 10(5):e0126256. PubMed ID: 25961288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endoplasmic reticulum polymers impair luminal protein mobility and sensitize to cellular stress in alpha1-antitrypsin deficiency.
    Ordóñez A; Snapp EL; Tan L; Miranda E; Marciniak SJ; Lomas DA
    Hepatology; 2013 May; 57(5):2049-60. PubMed ID: 23197448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo.
    Chiu HW; Yeh YL; Wang YC; Huang WJ; Chen YA; Chiou YS; Ho SY; Lin P; Wang YJ
    PLoS One; 2013; 8(10):e76340. PubMed ID: 24130769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In silico modification of suberoylanilide hydroxamic acid (SAHA) as potential inhibitor for class II histone deacetylase (HDAC).
    Tambunan US; Bramantya N; Parikesit AA
    BMC Bioinformatics; 2011; 12 Suppl 13(Suppl 13):S23. PubMed ID: 22373132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The structural requirements of histone deacetylase inhibitors: Suberoylanilide hydroxamic acid analogs modified at the C3 position display isoform selectivity.
    Choi SE; Weerasinghe SV; Pflum MK
    Bioorg Med Chem Lett; 2011 Oct; 21(20):6139-42. PubMed ID: 21889343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
    Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
    Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
    Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA
    Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase inhibitors selectively suppress expression of HDAC7.
    Dokmanovic M; Perez G; Xu W; Ngo L; Clarke C; Parmigiani RB; Marks PA
    Mol Cancer Ther; 2007 Sep; 6(9):2525-34. PubMed ID: 17876049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.